Has Sreedevi Reddy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $27,688 in general payments to Sreedevi Reddy, MD across 655 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sreedevi Reddy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sreedevi Reddy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sreedevi Reddy, MD

Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1437169067

Payments from drug & device makers

$27,688in general payments, 2019–2025

Across 655 payments — averaging $42.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Corcept Therapeutics$7K
Echosens North America, Inc.$6K
Novartis$1K
Lilly USA, LLC$1K
Rhythm Pharmaceuticals, Inc.$1K
Abbott$873
plus $10K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Corcept Therapeutics	65	$6,511
Echosens North America, Inc.	11	$6,300
Novartis	4	$1,445
Lilly USA, LLC	67	$1,238
Rhythm Pharmaceuticals, Inc.	14	$1,095
Abbott	41	$873
AstraZeneca(2 entities)	32	$868
Amgen(2 entities)	45	$862
Recordati_rare_diseases_inc.	11	$674
Novo Nordisk	47	$611
Insulet Corporation	20	$590
Mannkind Corporation	22	$559
AbbVie	23	$503
Dexcom, Inc.	21	$452
Sanofi-aventis U.S. LLC	27	$448
Boehringer Ingelheim	17	$417
BETA Bionics, Inc.	31	$338
Madrigal Pharmaceuticals	4	$335
Medtronic(2 entities)	9	$324
Xeris Pharmaceuticals, Inc.	18	$297
Amneal Pharmaceuticals LLC	23	$288
Cequr Corporation	4	$260
Antares Pharma, Inc.	15	$249
Radius Health, Inc.	10	$240
Neurocrine Biosciences, Inc.	3	$203
Sequel Med Tech, LLC	4	$201
Bayer	9	$155
Lifescan, Inc.	4	$136
Amarin Pharma, Inc.	4	$133
Ascendis Pharma Endocrinology Inc	5	$129
Janssen Scientific Affairs, LLC	1	$125
Tandem Diabetes Care, Inc.	2	$115
Halozyme Inc	4	$79
Tolmar, Inc.	4	$67
Johnson & Johnson	6	$65
Valeritas, Inc.	3	$52
Astellas Pharma US Inc	2	$50
Therapeuticsmd, Inc.	2	$43
Sandoz	1	$31
Kyowa Kirin, Inc.	1	$30
Merck	2	$26
Shire North American Group Inc	2	$25
Vivus LLC	2	$24
Chiesi USA, Inc.	1	$24
Zealand Pharma US, Inc.	1	$22
Amryt Pharma Holdings Ltd	1	$21
Exact Sciences	1	$20
Averitas Pharma Inc.	1	$20
Acerus Pharmaceuticals Corporation	1	$18
Almatica Pharma LLC	1	$17
Companion Medical, Inc.	1	$16
Acella Pharmaceuticals, LLC	1	$14
Clarus Therapeutics Inc.	1	$14
Endo Pharmaceuticals Inc.	1	$13
Esperion Therapeutics, Inc.	1	$13
Intuity Medical Inc	1	$12

How this compares

$27,688 in reported general payments places this provider in the 85th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona →

Medicare billing

Part B allowed, 2024

$587,217

Medicare patients

1,051

Services billed

18,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Scottsdale

Amir HarariScottsdale$361K
Kristina BlohmScottsdale$220K
Andrea FerencziScottsdale$137K
Abdul Razzak AlamirScottsdale$34K
Grace Zlaket MattaScottsdale$17K
Heather SaranScottsdale$14K
Chandana MishraScottsdale$11K
Vincent LiouScottsdale$10K
Kimberlee BrontsemaScottsdale$9K
Dena HaddadScottsdale$8K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →